Astromech Acquires Form Bio, Bringing Together Evolutionary AI and Genetic Medicine Design Under One Directive
DALLAS, Nov. 17, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Astromech Acquires Form Bio, Bringing Together Evolutionary AI and Genetic Medicine Design Under One Directive
PR Newswire
DALLAS, Nov. 17, 2026
The combined company takes researchers from evolutionary insight to tested genetic constructs, with applications in human therapeutics, genome engineering, and animal health
DALLAS, Nov. 17, 2026 /PRNewswire/ — Astromech, an AI company developing predictive models of biological change, today announced the acquisition of Form Bio in an all-stock transaction valued at $230 million. The acquisition brings Form Bio’s intellectual property, selected contracts and assets, and team into Astromech, combining evolutionary modeling with tools for designing genetic medicines and improving their manufacturability.
The combination brings together Astromech’s use of evolutionary data to predict biological function with Form Bio’s tools for designing genetic medicines that researchers can build and test. DNA sequences conserved across hundreds of millions of years can offer clues to important biological functions and inform therapeutic design. By connecting those insights with design capabilities, the companies aim to help researchers address quality challenges earlier in development, reducing unwanted components at the design stage and potentially lessening the need for downstream purification.
Andrew Busey, Form Bio’s co-founder and former CEO, has been named Chief AI Officer and Head of Technology at Astromech.
“Form Bio began by solving the computational challenges discovered from de-extinction and has grown into a company building foundation models for the design of human therapeutics,” said Busey. “Our work with customers and partners has shaped that evolution, moving us from analyzing biological data to helping design genetic medicines. Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make.”
Astromech’s models draw on data across species and evolutionary time to understand how biological functions emerged and predict how they may change. Form Bio complements this approach with AI-powered tools for designing genetic medicines, optimizing gene therapy vectors and manufacturing, and assessing genomic quality. Together, these capabilities aim to help researchers move from identifying evolutionary patterns to designing and testing genetic constructs, with applications in human therapeutics, genome engineering, and animal health.
Form Bio has spent years building foundation models for genomics—learning the grammar of regulatory and coding sequence directly from data, and applying it to the design and development of human therapeutics. Its capabilities support genetic medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies, and Solid Biosciences.
Form Bio’s work with Cure Rare Disease on Duchenne muscular dystrophy increased full-genome content from 13% to 59% in less than 30 days through promoter sequence-level redesign, with the program has now advanced in vivo preclinical studies. In a separate program, coding-sequence optimization alone increased full-genome content from approximately 2% to approximately 45%, with expression held at baseline.
“Form Bio’s AI-driven design platform is helping us rapidly evaluate and prioritize gene therapy constructs across multiple programs,” said Adrien Savy, Ph.D., Director of Discovery Science at Coave Therapeutics. In previously published testimonials, Taysha Chief Technology Officer Frederick Porter, Ph.D., highlighted Form Bio’s data infrastructure and analysis support for streamlined sample testing, while Solid Biosciences Chief Technology Officer Paul Herzich emphasized its contribution to accelerating therapeutic development toward the clinic.
Both companies are part of the Colossal Biosciences ecosystem. Form Bio launched in September 2022, subsequently expanding its computational capabilities into genetic medicine and genome engineering, and has raised more than $40 million in venture financing. Astromech emerged from Colossal’s work in comparative genomics, ancient DNA, and computational biology and has raised more than $60 million to date.
About Form Bio
Form Bio is a cutting-edge research and discovery platform for individuals and enterprises in life sciences. With the most accessible, comprehensive and collaborative platform in the field, Form Bio empowers scientists to efficiently and effectively harness the proliferation of data and computing power that has transformed the science of discovery. Form Bio offers end-to-end integration of the discovery process with intuitive and easy-to-use software applications, combined with an open and adaptable collaborative environment. Form Bio was developed within Colossal Biosciences and co-founded by Ben Lamm, Andrew Busey, and Kent Wakeford. For more information on Form Bio, please visit www.formbio.com.
About Astromech
Astromech is an AI company building a predictive model of biology. Combining deep learning across multi-species genomic and functional data with Bayesian reconstruction of ancestral sequence and regulatory state, Astromech is developing a unified biological intelligence architecture designed to predict how living systems change, identify where they are most vulnerable, and surface the regulatory mechanisms driving both. Astromech was co-founded by George Church and Ben Lamm and is headquartered in Dallas, Texas.For more information on Astromech, please visit www.astromech.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/astromech-acquires-form-bio-bringing-together-evolutionary-ai-and-genetic-medicine-design-under-one-directive-302942460.html
SOURCE Form Bio


